Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It
Posted in

Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It

“Giant cell arteritis requires ongoing management, but it does not necessarily require continuous treatment.” In 2017, tocilizumab (Actemra), a biologic drug that inhibits interleukin-6 (IL-6), was FDA-approved for giant cell arteritis — an inflammation of…

Nearly Half of Giant Cell Arteritis Patients on Actemra for a Year Stay in Remission After Stopping It Read More
The Arthritis Symptoms That Matter to Patients May Not Always Be the Ones They Discuss with Their Doctor
Posted in

The Arthritis Symptoms That Matter to Patients May Not Always Be the Ones They Discuss with Their Doctor

One of the main reasons people with arthritis visit the rheumatologist frequently — every three months is common among patients with inflammatory arthritis — is for doctors and patients to assess how arthritis patients are…

The Arthritis Symptoms That Matter to Patients May Not Always Be the Ones They Discuss with Their Doctor Read More
error: Content is protected !!